1. Home
  2. NXTC vs SWAG Comparison

NXTC vs SWAG Comparison

Compare NXTC & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextCure Inc.

NXTC

NextCure Inc.

SELL

Current Price

$6.83

Market Cap

24.8M

Sector

Health Care

ML Signal

SELL

Logo Stran & Company Inc.

SWAG

Stran & Company Inc.

SELL

Current Price

$1.23

Market Cap

29.1M

ML Signal

SELL

Company Overview

Basic Information
Metric
NXTC
SWAG
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
29.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
NXTC
SWAG
Price
$6.83
$1.23
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $20.00
N/A
AVG Volume (30 Days)
★ 51.7K
20.5K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.82
EPS
N/A
★ 0.06
Revenue
$22,378,000.00
★ $116,191,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$19.67
Revenue Growth
N/A
★ 40.58
52 Week Low
$1.55
$1.14
52 Week High
$15.74
$2.70

Technical Indicators

Market Signals
Indicator
NXTC
SWAG
Relative Strength Index (RSI) 54.35 34.16
Support Level $4.28 N/A
Resistance Level $6.66 $1.84
Average True Range (ATR) 0.80 0.09
MACD 0.09 -0.01
Stochastic Oscillator 69.35 10.55

Price Performance

Historical Comparison
NXTC
SWAG

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

Share on Social Networks: